CMV vaccine for stem cell transplant recipients
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You are planning to receive a half-matched stem cell transplant for certain blood cancers (like leukemia, lymphoma, or myelodysplastic syndrome).
- You have been infected with CMV in the past (CMV seropositive).
- You are willing to be followed for one year after your transplant.
- Your donor is between 18 and 75 years old and is a half-matched family member who can donate stem cells.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
This trial is for people with high-risk acute lymphoblastic leukemia who are getting a stem cell transplant from a family donor. After transplant, you'd receive a treatment that combines specially designed immune cells (CAR T cells) that target your leukemia, plus a vaccine that helps those cells work better.
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.